Heart valve disease has been on the rise, with an alarming increase of over 60% in morbidity over the last decade. For individuals over 75, this figure skyrockets to over 160%. The impact is staggering, affecting more than 10% of this age group with clinically relevant mitral valve disease. But amidst these challenges, there’s hope on the horizon. Introducing HVR Cardio, a pioneering Finnish cardiovascular device company dedicated to revolutionizing mitral valve repair. Their innovative approach, centered around proprietary helix technology, aims to tackle this pressing issue head-on. Their mission is clear: to develop solutions that are not only effective but also faster, easier to use, and less invasive.
At Almaral, we believe in investing in transformative ventures that have the potential to change lives. That’s why we’re thrilled to announce our partnership with HVR Cardio as one of the key investors in their latest funding round. Together, we’re paving the way for groundbreaking advancements in cardiovascular care.